Bipolar Depression Treatment: Medications, Therapy, and Evidence
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Bipolar depression treatment addresses depressive episodes within bipolar I or bipolar II disorder while protecting against a return of mania, hypomania, mixed symptoms, and recurrent depression. Effective care usually combines a carefully selected medication strategy, ongoing clinical assessment, psychological support, and a long-term relapse-prevention plan. Treatment choice depends on the current episode, previous mood episodes, prior responses, coexisting conditions, safety risks, and the person's preferences. These principles are reflected in the CANMAT/ISBD evidence update, the 2023 VA/DoD guideline, and NICE recommendations.
The central clinical distinction is the phase being treated. An intervention with good evidence for acute mania may have little evidence for bipolar depression; a medicine that reduces depressive symptoms over several weeks may not be proven to prevent future manic episodes. This guide focuses on acute bipolar depression and the transition into recovery. Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care addresses the broader treatment pathway.
For additional clinical context, see Antidepressants in Bipolar Disorder: Mood Switching Risk and Clinical Guidance and Treatment for Acute Mania: Safety, Medication, and Specialist Care.
What counts as bipolar depression, and why treatment is different
A bipolar depressive episode can involve persistent low mood or loss of interest, impaired concentration, reduced energy, changes in sleep or appetite, feelings of worthlessness, and thoughts of death. A major depressive episode generally requires symptoms present most of the day, nearly every day, for at least two weeks, with distress or functional impairment. The diagnosis of bipolar disorder depends on a lifetime history that includes mania for bipolar I or hypomania together with major depression for bipolar II. Ordinary mood variability, an online score, and isolated depressive symptoms do not establish a bipolar diagnosis. See the NIMH clinical overview and How Is Bipolar Disorder Diagnosed? Clinical Assessment Explained.
In bipolar depression, clinicians assess whether the person is experiencing a purely depressive presentation or depression with simultaneous manic symptoms such as marked activation, racing thoughts, agitation, decreased need for sleep, or impulsivity. Mixed features can alter the medication risk-benefit balance, especially for antidepressants. Clinicians also evaluate psychosis, suicidal thoughts, catatonia, substance exposure, medical conditions, and the possibility that an apparently unipolar depressive episode belongs to a bipolar course. When the classification is uncertain, the treatment plan must account for that uncertainty rather than rely on one questionnaire.
How clinicians select an acute treatment
The initial decision is guided by severity and urgency. Someone who can eat, sleep, remain safe, and attend outpatient visits may be treated with closely monitored medication and structured psychotherapy. Severe suicidal intent, inability to maintain food or fluid intake, catatonia, psychotic depression, or major loss of judgment can require urgent psychiatric assessment, hospital-level care, or consideration of electroconvulsive therapy. The VA/DoD guideline explicitly separates urgent care from routine medication selection.
A proper medication review includes exact prior drug trials and duration, current prescriptions, adherence barriers, adverse reactions, kidney or thyroid disease, metabolic risk, pregnancy potential, drug interactions, substance use, sleep disruption, and any history of antidepressant-associated mania. A shared decision should identify the goal of the current intervention: reduction of depressive symptoms, protection against mood switching, restoration of function, and a plan for maintenance once improvement occurs. CANMAT/ISBD recommends switching to or adding an alternative evidence-supported agent when a genuinely adequate first trial is ineffective, taking response and polypharmacy into account.
Evidence-based medication options for acute bipolar depression
No single medication is the best choice for every person. The main evidence-supported options include certain second-generation antipsychotics, lithium, and lamotrigine, with indications and strength of evidence varying by bipolar subtype and treatment phase. Different guidelines also rank options differently because they weigh trial quality, previous use, adverse effects, and the healthcare setting in different ways. The CANMAT/ISBD update ranks quetiapine, lithium, lamotrigine, cariprazine, and specified uses of lurasidone among first-line options for bipolar I depression; the VA/DoD guideline puts considerable emphasis on quetiapine and other specifically supported acute agents.
Quetiapine
Quetiapine has randomized-trial evidence for acute bipolar depression and is a prominent option across major guidance. It is used for depressive episodes associated with bipolar I and bipolar II disorder, with evidence that spans more than one illness phase. Its advantages must be weighed against sedation, daytime fatigue, increased appetite, weight gain, metabolic changes, low blood pressure on standing, and movement-related adverse effects. A person who drives, has diabetes risk, struggles with excessive sleepiness, or has previously gained substantial weight on medication may view these tradeoffs differently. NICE and CANMAT/ISBD support its use but emphasize individual tolerability.
Lurasidone
Lurasidone has evidence for acute bipolar I depression as a single agent and, in adults, as an addition to lithium or valproate. Its bipolar-depression labeling must not be generalized to every bipolar subtype or to long-term prevention of mania. Restlessness, akathisia, nausea, and other movement-related effects may limit use; drug interactions and liver or kidney function can change prescribing decisions. Food matters because the official U.S. prescribing information specifies administration with a meal containing at least 350 calories to achieve expected absorption. Individuals should follow their own prescriber's instructions rather than experiment with administration.
Cariprazine
Cariprazine is an evidence-supported acute option for adults with bipolar I depression. Potential adverse effects include akathisia, restlessness, nausea, extrapyramidal symptoms, and metabolic effects; its long-acting active metabolites complicate assessment of the timing of benefit, adverse reactions, and medication changes. Its U.S. authorization for bipolar depression applies to adults with bipolar I disorder, which should be distinguished from its other indications. CANMAT/ISBD includes it in its acute treatment hierarchy, and the official product label describes indication-specific precautions.
Lumateperone
Lumateperone has placebo-controlled evidence for acute depressive episodes associated with bipolar I and bipolar II disorder in adults, both as monotherapy and with lithium or valproate. It may be considered where side-effect preferences or previous medication trials favor it. Sedation, dizziness, nausea, and drug-interaction considerations still matter, and emerging long-term data should not be confused with the acute evidence base. The U.S. FDA labeling specifies the bipolar I and II depression indications; CANMAT/ISBD and VA/DoD contextualize its role differently.
Olanzapine combined with fluoxetine
The fixed combination of olanzapine and fluoxetine has evidence for bipolar depressive episodes and appears in major guidelines as an option. This is a specific combined treatment, not evidence that antidepressant monotherapy is an equivalent strategy. Olanzapine may carry substantial appetite, weight, glucose, and lipid effects, while the fluoxetine component introduces antidepressant-related cautions, interactions, and monitoring needs. NICE lists olanzapine plus fluoxetine as an initial option in its UK algorithm; CANMAT/ISBD ranks it differently in the Canadian evidence hierarchy.
Lithium
Lithium has a central role in bipolar disorder because it can reduce recurrence of mood episodes, and it has evidence supporting suicide-risk reduction in some populations, although results and individual outcomes vary. Its acute antidepressant effects are less straightforward than those of several agents specifically tested for short-term bipolar depression, and guidelines may use it alone or with another therapy. Lithium requires periodic blood-level measurement and monitoring of kidney and thyroid function; dehydration, major salt or fluid changes, and interactions with certain pain medicines, diuretics, and blood-pressure drugs can raise toxicity risk. NIMH, NICE, and CANMAT/ISBD describe these considerations.
Possible signs of lithium toxicity include worsening tremor, vomiting, diarrhea, marked unsteadiness, confusion, or unusual drowsiness. These symptoms need prompt medical assessment. The prescriber determines the target serum level according to illness phase, age, kidney function, concurrent medicines, and tolerability. A blood level is a clinical monitoring tool; it does not replace symptom assessment. Patients should never independently adjust lithium because of a perceived lack of rapid antidepressant benefit.
Lamotrigine
Lamotrigine is commonly considered for depressive vulnerability and prevention of depressive recurrence in bipolar disorder. Its acute bipolar-depression evidence is more heterogeneous, and the slow titration needed for safety makes it unsuitable as a rapid response intervention in an emergency. Its recognized role in bipolar I maintenance also must be separated from a claim that it acutely treats mania. CANMAT/ISBD includes lamotrigine among acute options for bipolar I and as a second-line acute option for bipolar II, while NICE positions it among options if other treatments are inappropriate or ineffective.
Lamotrigine can cause serious rashes, including Stevens–Johnson syndrome or toxic epidermal necrolysis. New rash, particularly with fever, mucosal involvement, blistering, or systemic illness, calls for immediate professional assessment. Dose escalation, prolonged interruptions, and interactions with valproate require prescribing precision; restarting after missed doses may call for a new titration schedule determined by the clinician. Contraceptive medicines containing estrogen can alter lamotrigine exposure. These considerations make a medication reconciliation and a written safety plan essential.
Valproate and other medications with a narrower acute-depression role
Valproate is used for some bipolar presentations, particularly mania and maintenance contexts, but it should not be assumed to be the strongest first-choice antidepressant treatment merely because it is a mood stabilizer. Specialized guidelines rank it differently for acute bipolar depression. Valproate carries major reproductive and developmental risks, possible liver injury, pancreatitis, platelet and blood-count abnormalities, and important interactions; people who are pregnant or could become pregnant require specialist discussion of the safest alternatives and applicable regulations. NICE safety guidance emphasizes restrictions and monitoring, while CANMAT/ISBD differentiates its depression evidence from other phases.
Aripiprazole is useful in other bipolar phases but standard oral aripiprazole monotherapy did not establish efficacy as an acute bipolar I depression treatment in the way some other antipsychotics have. Carbamazepine, other anticonvulsants, sedatives, and off-label augmentation approaches have specific contexts and variable evidence; their usefulness must be judged for the exact clinical problem rather than as interchangeable antidepressant substitutes. The CANMAT/ISBD treatment table explicitly marks standard aripiprazole monotherapy as not recommended for acute bipolar I depression.
Bipolar I and bipolar II depression are treated with different evidence hierarchies
Bipolar II involves episodes of major depression and hypomania without a lifetime manic episode; its depressive burden can be serious and disabling. Treatment evidence differs from bipolar I. In the CANMAT/ISBD bipolar II hierarchy, quetiapine is the first-line acute option, while lithium, lamotrigine, lumateperone, ECT, and selected antidepressant strategies occupy different subsequent positions. The existence of a drug approval for bipolar I does not imply approval for bipolar II, and a trial with mixed populations must be interpreted by its actual results for each subgroup.
The choice also depends on whether depression is nonmixed, whether hypomanic switches occurred with past antidepressant exposure, the person’s sleep pattern, and past clinical response. A diagnosis of bipolar II must never be characterized as a mild version of bipolar I; the conditions differ in episode polarity, clinical course, and treatment questions. People need a longitudinal specialist assessment before choosing a therapy on the basis of a subtype label alone. For diagnostic context see Bipolar II Disorder: Symptoms, Diagnosis, and Treatment.
Are antidepressants safe or effective in bipolar depression?
Antidepressants are not the default stand-alone treatment for bipolar I depression. They can be associated with activation, hypomania or mania, mixed symptoms, and mood instability in susceptible individuals; the probability varies by patient, medicine, prior episodes, and study design. The NIMH overview and CANMAT/ISBD guidance advise against antidepressant monotherapy in bipolar I. For some people who have persistent nonmixed depression despite an appropriate first-line treatment, an SSRI or bupropion may be considered as a monitored adjunct, with a clear plan to detect emerging manic symptoms.
Bipolar II evidence is more nuanced: selected nonmixed depressive presentations have been studied with sertraline or venlafaxine under specialist supervision. This does not make all antidepressants equally safe or clinically preferable. A history of mixed features, rapid cycling, antidepressant-related switching, or substantial activation changes the balance. Stopping an antidepressant suddenly can itself cause withdrawal symptoms or worsening symptoms; medication tapering and transitions should be planned with the treating clinician. CANMAT/ISBD provides subtype-specific distinctions.
The evidence also illustrates why acute response and maintenance require different questions. A randomized trial of adjunctive escitalopram or bupropion after remission of bipolar I depression did not show a statistically significant advantage of continuing treatment for 52 weeks versus discontinuing after eight weeks on its primary composite outcome; depressive and manic recurrence patterns differed and the trial ended before full recruitment. This nuanced result does not justify automatic lifelong continuation or an abrupt universal stop rule. It calls for individualized discussion of depressive recurrence and switch risk. See Yatham et al., New England Journal of Medicine (2023).
What psychotherapy contributes
Psychotherapy supports recovery by improving understanding of illness patterns, treatment collaboration, behavioral activation appropriate to the episode, coping with depression, family communication, and relapse recognition. For many people it complements medication rather than replacing needed pharmacotherapy, particularly in severe bipolar depression. A systematic review and network meta-analysis of 39 randomized trials found that structured psychosocial treatments were associated with lower recurrence and that CBT showed benefit for residual depressive symptoms. Crucially, relatively few trials enrolled participants during an acute mood episode; recurrence-prevention findings cannot automatically be rebranded as evidence of rapid acute antidepressant action.
Cognitive behavioral therapy
CBT adapted for bipolar disorder addresses depressive thought patterns, inactivity, avoidance, realistic pacing, and early signs of switching or relapse. It works best when the clinician understands the possibility that sleep loss, overly intensive activation, or changing energy can signal mood instability rather than uncomplicated recovery. NICE recommends a psychological intervention developed specifically for bipolar disorder or appropriate structured psychological treatment and encourages therapists with bipolar expertise. Individual outcomes vary, and psychotherapy should be coordinated with medication review.
Family-focused therapy and psychoeducation
Family or conjoint approaches can help relatives identify changes in sleep, communication, conflict, stress, and crisis responses. Psychoeducation helps people recognize their illness course, understand treatment tradeoffs, identify early warning signs, and plan support without turning family members into amateur diagnosticians. The Miklowitz et al. meta-analysis associated several family and psychoeducational interventions with lower recurrence compared with treatment as usual. The strongest inference concerns adjunctive care and longitudinal functioning, not immediate resolution of a severe depressive episode.
Interpersonal and social rhythm therapy
Interpersonal and social rhythm therapy focuses on social relationships, regular daily timing, sleep-wake stability, and changes in routines that may destabilize mood. These are practical targets because irregular rhythms can interfere with medication adherence, functioning, and recovery, though a stable schedule alone does not cure bipolar depression. The psychotherapy evidence synthesis reports promising but less precise estimates for some specific modalities, emphasizing the importance of matching therapy to individual needs.
How quickly can treatment help, and how is response assessed?
Medication trials are generally evaluated over weeks with interim safety and symptom reviews; exact timelines depend on the drug, baseline severity, titration, side effects, and whether the episode has mixed or psychotic symptoms. Lamotrigine is introduced slowly; some antipsychotics can reduce symptoms sooner, although full functional recovery may take longer than an initial symptom score improvement. Clinicians track changes in mood, anhedonia, sleep, energy, cognition, daily functioning, adherence, side effects, suicidal thinking, and emerging hypomania or mania. VA/DoD and CANMAT/ISBD recommend measurement-informed review and treatment adjustment.
A treatment is not necessarily ineffective because the first few days are difficult, nor should adverse effects be ignored while waiting for benefit. An adequate trial requires a clinically reasonable duration at a tolerable therapeutic regimen and confirmation that the medication was actually taken in the prescribed way. Partial benefit can justify a different decision from complete nonresponse. Reassessment should look for diagnostic uncertainty, concurrent substance use, irregular sleep, medical illness, inadequate dose or duration, drug interactions, and barriers to psychotherapy access.
What if bipolar depression does not improve?
Persistent depression after one or more appropriate treatments warrants a structured reassessment of diagnosis, subtype, current mixed features, adherence, medication burden, and safety. The next step might be a switch within an evidence-supported acute treatment class, carefully planned augmentation, a targeted psychological intervention, or a higher level of care. The order differs according to previous responses and side effects; combinations can increase interaction and monitoring burdens. CANMAT/ISBD provides staged approaches, and the VA/DoD guideline includes a pathway for difficult-to-treat bipolar depression.
Electroconvulsive therapy
ECT is an established specialist treatment considered for severe, life-threatening, psychotic, catatonic, or treatment-resistant depression, especially when faster clinical improvement is necessary. It requires anesthesia and clinical monitoring and may cause transient confusion or memory problems; benefits and harms should be discussed within the urgency of the clinical situation. It is not interchangeable with standard antidepressant medication or casual brain stimulation. See the NIMH brain-stimulation guide and VA/DoD guideline.
Ketamine, esketamine, and other emerging approaches
Ketamine-based strategies and other treatments have been investigated in bipolar depression, but much of this evidence involves small or short studies, concurrent mood-stabilizing treatment, specialist settings, or outcomes that do not establish durable relapse prevention. Ketamine can alter perception, blood pressure, and judgment, and there are clinically important risks involving dissociation, misuse potential, and destabilization. Its role should be decided by an experienced clinical team, particularly when ECT or established agents are unsuitable. VA/DoD discusses ketamine in selected urgent or refractory pathways, while CANMAT/ISBD regards IV ketamine as a later-line adjunct.
Repetitive transcranial magnetic stimulation, light-based strategies, sleep deprivation procedures, and other adjuncts are under study in bipolar depression, but protocols, response durability, switch risk, and research quality vary. Light therapy can be clinically meaningful for some patients yet requires attention to the possibility of hypomanic activation and timing of exposure. Established acute treatments should not be displaced by a promising but less certain technique without an explicit specialist discussion of evidence and safety. See CANMAT/ISBD and NIMH brain-stimulation information.
Safety monitoring is part of effective treatment
Monitoring must be tailored to the drug and person. Lithium requires renal and thyroid monitoring and measured serum levels. Antipsychotics generally require attention to weight, blood pressure, glucose, lipids, sedation, akathisia, abnormal movements, and drug-specific interactions. Lamotrigine requires rash precautions and titration review. Valproate requires reproductive-risk discussion, liver and blood-count considerations, and interaction monitoring. Antidepressants require surveillance for activation, mixed symptoms, sleep reduction, suicidality, and switching. These are treatment-safety questions documented in NICE, NIMH, and VA/DoD.
Patients should be able to tell their clinician about missed doses, difficulties paying for medicines, alcohol or other substance use, supplements, nonprescription pain medicines, and major changes in sleep or hydration without fear of judgment. A written medication list shared across clinicians helps prevent accidental combinations. New severe rash, suspected lithium toxicity, profound confusion, inability to care for basic needs, or rapidly escalating manic symptoms require prompt assessment; these situations should not be handled by online dose advice.
Suicidal thoughts, psychosis, mixed states, and urgent care
Bipolar depression can be associated with suicidal thoughts, especially with severe hopelessness, agitation, mixed activation, substance use, or previous suicidal behavior. Asking directly about suicidal thinking is a normal element of clinical assessment. Immediate danger, a specific plan or intent to die, inability to remain safe, severe psychotic symptoms, catatonia, or extreme behavioral dysregulation requires emergency services or an emergency department now. In the United States, call or text 988 for crisis support; use the local emergency number if there is imminent danger. A friend or relative can remain with the person, help reduce access to lethal means, and support urgent evaluation. NIMH and VA/DoD emphasize risk recognition and coordinated care.
An urgent symptom escalation is also possible when depression seems to improve: a sudden sharp decrease in the need for sleep, severe agitation, racing thoughts, grandiosity, or impulsive risky behavior can indicate a manic or mixed transition rather than healthy recovery. This is especially important after a medication change. See Bipolar Disorder With Mixed Features: Symptoms, Risks, and Diagnosis and Early Warning Signs of Mania and Bipolar Relapse.
Pregnancy, adolescence, older age, and coexisting conditions
Pregnancy planning, pregnancy itself, and the postpartum period can change medication safety and relapse risks. Valproate deserves especially careful avoidance or restriction under applicable regulatory guidance; lithium, lamotrigine, and antipsychotics require individualized specialist risk-benefit and monitoring decisions. The potential harms of untreated severe illness also matter. The right pathway involves psychiatry and obstetric or perinatal expertise, not blanket advice to discontinue a useful medication. NICE provides specific recommendations and safety cross-references.
Children and teenagers cannot be treated as smaller adults: licensing, pediatric trial evidence, developmental effects, family participation, and suicidality monitoring differ. Older adults may have altered kidney clearance, more drug interactions, and greater vulnerability to falls, sedation, and cognitive effects. Coexisting anxiety, ADHD, substance problems, chronic pain, or sleep disorders also affect care without changing which cluster owns their primary diagnosis. The CANMAT/ISBD guidance discusses different age groups and populations, while NIMH outlines diagnostic and treatment fundamentals.
Moving from improvement to long-term stability
When an acute depressive episode improves, the clinical task shifts toward maintaining recovery and preventing depression, mania, or hypomania. A medication that worked acutely may be continued, modified, or paired with another preventive treatment according to its maintenance evidence, the person’s history, and tolerability. Lithium, quetiapine, and lamotrigine have different prevention profiles; evidence for an acute antidepressant effect should never be converted into a claim of guaranteed long-term protection. NICE describes lithium as a leading long-term option, and CANMAT/ISBD separates maintenance from acute treatment evidence.
A practical recovery plan includes consistent follow-up appointments, sustainable sleep timing, a strategy for missed medicines, monitoring of adverse effects, an early warning-sign list, crisis contacts, and a coordinated response to work or family stressors. Family members can offer observations and assistance while respecting autonomy and confidentiality. A relapse plan is especially useful because subtle changes often arise before a full mood episode; no tracker or smartwatch can diagnose a switch on its own.
Common misconceptions about bipolar depression treatment
A depressive phase does not mean the person has unipolar major depression; lifetime episode history matters. Bipolar II does not mean symptoms are too mild to need sustained care. An antipsychotic prescribed for bipolar depression is not proof that the person has schizophrenia. A mood stabilizer effective for mania is not automatically a proven acute antidepressant. Antidepressant monotherapy is not an interchangeable substitute for bipolar-specific treatment. These distinctions follow the phase-specific evidence in NIMH, NICE, and CANMAT/ISBD.
Another misconception is that treatment either works immediately or never will. Recovery is usually assessed across mood, safety, work or school function, sleep, relationships, and quality of life. Improvement can be uneven, and persistent symptoms warrant review. Evidence supports collaboration among the patient, psychiatrist, therapist, and chosen supporters; the best plan is one the person understands and can safely follow.
Frequently asked questions
What is usually the first medication for bipolar depression?
There is no single universal first medication. Quetiapine is prominent across major guidelines, while lurasidone, cariprazine, lumateperone, lithium, and lamotrigine occupy different guideline and subtype-specific roles. The selection depends on bipolar I versus bipolar II, prior response, mixed features, medical risks, and availability. See CANMAT/ISBD and VA/DoD.
Can bipolar depression be treated without medication?
Psychotherapy and support can make substantial contributions, but severe bipolar depression commonly requires medical evaluation and often pharmacotherapy. A plan that avoids medication should be discussed with a qualified clinician in light of past mania, episode severity, suicidality, and relapse risk. ECT is a non-drug specialist treatment for selected severe presentations, but it is a clinical procedure rather than a general substitute for follow-up care.
Is lamotrigine better than lithium?
Their evidence, benefits, and risks are different. Lamotrigine is particularly relevant to depressive recurrence and requires slow titration and rash precautions; lithium has broader maintenance evidence but needs kidney, thyroid, and blood-level monitoring. The right comparison depends on whether the objective is acute depression relief, prevention of depression, prevention of mania, or reduction of overall recurrence. See NICE and CANMAT/ISBD.
Why are antidepressants used cautiously?
Bipolar depression can coexist with vulnerability to mania, hypomania, or mixed states. For bipolar I, antidepressant monotherapy is generally discouraged; carefully selected adjunctive use has narrower evidence and requires monitoring. Bipolar II data are different and remain individualized. See CANMAT/ISBD and the 2023 randomized trial.
What happens if several treatments fail?
Clinicians recheck the diagnosis, trial adequacy, adherence, concurrent conditions, and medication interactions before considering a switch, combination, ECT, or a specialized intervention. Poor response does not justify unmonitored escalation or a series of abrupt medication changes. The VA/DoD pathway gives a structured approach.
How do I know when bipolar depression needs emergency care?
Suicidal intent or a specific plan, inability to stay safe, psychosis with major impairment, refusal or inability to take food or fluids, catatonia, or rapidly worsening mixed or manic symptoms requires urgent assessment. Contact emergency services or go to an emergency department for immediate danger; in the United States, 988 offers crisis support.
Related Articles
References
DailyMed. (2025). LATUDA (lurasidone): U.S. prescribing information.
DailyMed. (2025). VRAYLAR (cariprazine): U.S. prescribing information.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus / PubMed Central full text.
Miklowitz, D. J., Efthimiou, O., Furukawa, T. A., et al. (2021). Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry, 78(2), 141–150. doi:10.1001/jamapsychiatry.2020.2993.
National Institute for Health and Care Excellence. (2014, subsequently amended). Bipolar disorder: assessment and management (CG185). Clinical recommendations.
National Institute of Mental Health. (n.d.). Bipolar disorder: Diagnosis and treatment.
National Institute of Mental Health. (n.d.). Brain stimulation therapies.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). Management of Bipolar Disorder: VA/DoD Clinical Practice Guideline. Guideline and accompanying materials.
U.S. Food and Drug Administration. (2025). CAPLYTA (lumateperone): U.S. prescribing information.
Yatham, L. N., et al. (2023). Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. New England Journal of Medicine, 389, 430–440. doi:10.1056/NEJMoa2300184.